Aparito are pleased to be sharing the latest research from our rare disease pipeline with the expert scientific community at the WORLDSymposium™ – on February 11th & 12th.
Five posters are being presented in collaboration with Prevail Therapeutics, Kantar Health, The International Gaucher Alliance (IGA) and several independent consultants.
February 11, 2:30 – 3:30pm EST (7:30 – 8:30 GMT)
| Lysosomal Disorder | Poster Number | Abstract Title | Authors |
| Gaucher disease (GD) (types 1 and neuronopathic (nGD) Late Onset Tay- Sachs (LOTS) Niemann Pick disease – type C (NP-C) | 50 | ‘Decentralised convenience: Digitised clinical assessment for impaired ambulation.’ | Daniel Lewi, Elin Haf Davies & Obuchinezia Anyanwu (Aparito) |
| Lysosomal Storage Disorders – Gaucher Disease (GD2) | 51 | ‘Assessing paediatric feeding in lysosomal diseases using remote smartphone video technology.’ | EH Davies (Aparito) EA Yousef (Prevail Therapeutics) R Howarth (Speech/Language Therapist – Royal Manchester Children’s Hospital ) |
| Gaucher disease (GD) (types 1 and neuronopathic (nGD) Late Onset Tay-Sachs (LOTS) Niemann Pick disease – type C (NP-C) MPSIII Sanfilippo Pompe Disease Gaucher disease (Type 2) | 137 | ‘Aparito’s six-year journey in lysosomal disorders.’ | Daniel Lewi, Elin Haf Davies & Obuchinezia Anyanwu (Aparito) |
| Lysosomal Storage Disorders | 138 | ‘The new normal: Smartphone technology and its impact on the logistics of healthcare.’ | Daniel Lewi, Elin Haf Davies & Obuchinezia Anyanwu (Aparito) |
February 12, 2:30 – 3:30pm EST (7:30 – 8:30 GMT)
| Lysosomal Disorder | Poster Number | Abstract Title | Authors |
| Neuronopathic Gaucher disease – Gaucher Disease – Type 2 and Type 3 | LB-08 | ‘Development of quality of life measures in neuronopathic Gaucher disease: Qualitative research findings’ – | D Elstein (independent consultant) T Collin-Histed, M Collin (International Gaucher Alliance) E H Davies (Aparito) D Jaffe , M Fronstin, G Wayser, K Beusterien (Kantar Health) |